CLEAN-PCD: a phase 2 study of idrevloride in primary ciliary dyskinesia: Thomas Ferkol, ERS 2023
CLEAN-PCD is a phase 2 randomized, double-blind, placebo-controlled crossover trial investigating the efficacy and safety of idrevloride in primary ciliary dyskinesia (PCD). It was a pleasure to talk with Dr. Thomas Ferkol (UNC Department of Pediatrics, Chapel Hill, NC, USA) around the mechanism of action of idrevloride, the methodology of the CLEAN-PCD study, and the safety and efficacy findings of the study.
The abstract ‘Safety and efficacy of idrevloride in people with primary ciliary dyskinesia: a double-blind, randomized, placebo-controlled crossover trial (CLEAN-PCD).’ was presented at ERS 2023, 9 – 13 September 2023.
Questions
- Could you tell us a little about primary ciliary dyskinesia (PCD) and the unmet needs in its treatment? (0:13)
- What is the mechanism of action of idrevloride and what was the rationale for the CLEAN-PCD study? (1:42)
- Please could you describe the methodology of the phase 2 CLEAN-PCD trial? (2:51)
- What were the safety and efficacy findings of the study? (3:26)
- What will be the next steps in realising the potential of idrevloride in this indication? (4:05)
Disclosures: Thomas Ferkol discloses receiving grant/research support from the National Institutes of Health (HL096458, TR003860), ReCode Therapeutics (Observational study, Parion Sciences (Clinical drug trial); serving on advisory boards for ReCode Therapeutics PCD Clinical Steering Committee and receiving honoraria from the Cystic Fibrosis Foundation.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS Annual Meeting.
